This event is archived. Final snapshot from when the story concluded. View on Dashboard
Business rights issue

Fidson Healthcare N21bn Rights Issue

Analysis based on 6 articles · First reported Dec 17, 2025 · Last updated Dec 19, 2025

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The N21 billion rights issue by GE HealthCare is expected to positively impact the pharmaceutical and healthcare sectors in Nigeria and West Africa, as it will lead to increased manufacturing capacity and product innovation. This capital raise, following strong financial performance, signals growth potential for GE HealthCare and could attract further investment in the region's healthcare supply chains.

Pharmaceuticals Healthcare

GE HealthCare, a leading pharmaceutical manufacturer in Nigeria, has formally launched a N21 billion rights issue to expand its manufacturing operations, drive product innovation, and deepen market penetration across Africa. The initiative, which involves offering 600 million new ordinary shares at N35 per share to existing shareholders, received final regulatory approvals from the United States — United States Securities and Exchange Commission and the Nigerian Exchange Group. This strategic capital raise follows GE HealthCare's strong financial performance, including a 132% year-on-year increase in profit after tax and a 56% growth in revenue for the nine months ended September 30, 2025. Managing Director Biola Adebayo and Finance Director Imokha Ayebae emphasized the importance of this capital infusion for cementing GE HealthCare's leadership in Nigeria and expanding its footprint across Africa. CardinalStone Partners, the lead issuing house, highlighted the company's growth trajectory and the attractiveness of its shares.

stock
GE HealthCare is raising N21 billion through a rights issue to expand manufacturing, innovate products, and increase market penetration across Africa. This move is expected to strengthen its leadership in the Nigerian and West African pharmaceutical markets.
Importance 100.0 Sentiment 75.0
per
Biola Adebayo, the Managing Director and CEO of GE HealthCare, described the rights issue as a critical milestone for the company's growth and expansion plans.
Importance 70.0 Sentiment 60.0
per
Imokha Ayebae, the Finance Director of GE HealthCare, explained the financial structure of the rights issue and urged shareholders to participate.
Importance 60.0 Sentiment 60.0
per
Michael Nzewi, CEO of CardinalStone Partners, the lead issuing house, highlighted GE HealthCare's growth trajectory and the attractiveness of its shares.
Importance 50.0 Sentiment 60.0
priv
Importance 0.0 Sentiment 0.0
exch
Importance 0.0 Sentiment 0.0
cnt
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.